Rating: Neutral ｜ Target Price: HKD 12.9-17.5 (base-case fair value range, midpoint ~HKD 15.1) ｜ Current price: HKD 13.45 (close on 2026-09-01) ｜ Probability-weighted fair value ~HKD 15.25 (~+13.4% vs. current) ｜ Time horizon: 12 months
| Item | Previous (2026-07-03) | Current (2026-09-02) | Rationale for Change |
|---|---|---|---|
| Rating | Neutral | Neutral | Maintained—after a 28% share-price decline, valuation has moved from "fair-to-rich" back to "fair-to-cheap," but probability-weighted upside of only ~13% is insufficient to support a shift |
| Confidence | 0.55 | 0.55 | Maintained—fundamental evidence has strengthened (interim results +31.8%, quota freeze confirmed), but demand-side leading indicators have weakened and the expectation gap has narrowed; the two offset each other |
| Target price range | HKD 16-18 | HKD 12.9-17.5 | Lowered: exit multiple anchor changed from estimated midpoint (~12-14x) to a tangible anchor of H-share chemical comparables (8-10x, referencing Sinopec Kantons' current price and A/H discount); meanwhile, the zero-growth EPV was actually raised (~HKD 12.5 → 15.0, due to net cash rising from RMB 5.0 to 6.07 billion and upward revision of mid-cycle earnings for fluoropolymers)—valuation midpoint shifted down while the floor rose; the current price has moved from "above fair value" into the lower part of the base-case range |
| Valuation judgment | Fair-to-rich | Fair-to-cheap | Share price fell from HKD 18.62 to 13.45 (-27.8%) while interim net profit attributable rose +31.8% and the 2027 quota draft confirmed a total freeze—the pullback is mainly driven by fund flows (no interim dividend, southbound selling) and export rumors, not fundamental deterioration |
Calibration note on this revision: both the target-price cut and the valuation-judgment change are supported by clear new facts (August 20 interim results, August 24 quota draft, sector fund-flow data since mid-July)—not view drift.
The quota system has rewritten China's refrigerants industry as an "administratively franchised" business. Leveraging its incumbent position as the largest R22 quota holder nationally (29.46%) and second-largest R32 holder (20.09%), Dongyue Group delivered 2026H1 net profit attributable of RMB 1.027 billion (+31.8%) with a gross margin of 37.18%, with the silicones and fluoropolymer twin engines both delivering. Yet the share price has retraced ~40% from the June high of HKD 22.34 to HKD 13.45, with PB falling below 1x: the current price implies normalized attributable earnings of ~RMB 1.39 billion (back-solved at WACC 10%), roughly the actual earnings level of 2023-24 before the quota regime—the market has already priced in "a moderate pullback in refrigerant earnings in 2027." We judge this pricing slightly low but only modestly so: mid-cycle earnings power of ~RMB 1.6 billion, base-case fair value of HKD 12.9-17.5, probability-weighted upside of ~+13.4%. The key constraint: R32 spot prices sit at roughly the 100th historical percentile while air-conditioner production schedules keep weakening, and the annual long-term contract negotiations (Dec 2026-Jan 2027) are the true repricing point; upside triggers are the official quota document in October, stable Q4 long-term contracts, and dividend actions at the March 2027 annual results. Neutral rating; wait for richer odds or clearer catalyst delivery.
Primary share-price driver (next 6-12 months): the central tendency of refrigerant prices—the direction of R32 long-term contract and spot prices. 78-88% of price changes pass directly through to segment results (pass-through of 87.5% in FY2025 and 78.2% in 2026H1); every RMB 10,000/ton move in R32 affects attributable earnings by ~RMB 0.4-0.5 billion. Chain to watch: Q4 long-term contract fixing in Sep-Oct → annual contract negotiations Dec-Jan → monthly production schedules from CCIIN.
Verifiable expectation gap: The current price's reverse-EPV implies normalized attributable earnings of ~RMB 1.39 billion (WACC 10% basis), ~14% below our mid-cycle estimate (~RMB 1.62 billion) and ~35% below FY2026E (RMB 2.05-2.2 billion). Two constraints must be honestly flagged: first, this conclusion is discount-rate sensitive—at WACC 12% the implied value rises to ~RMB 1.67 billion, nearly matching the mid-cycle estimate, invalidating the "market severely undervalues" claim; the accurate statement is "market pricing already embeds a neutral path of R32 average prices falling to around RMB 55,000/ton." Second, the sell-side anchor (current basis; Futu aggregation 2026-08-31: mean HKD 18.12, low 15.25, high 21.67) is ~35% above the current price, with the lowest target still 13% above it—indicating no pessimistic bids among institutions; the discount stems from fund flows and H-share liquidity, not covering analysts.
Catalysts for validation and falsification conditions: Official quota document at end-October (draft confirmed total frozen at 1.853 billion tCO₂; probability ~85%); Q4 long-term contract quarter-on-quarter direction (flat or rising = base case reinforced; a cut of more than 5% = peak-earnings narrative confirmed); whether FY2027 March annual results show attributable earnings above RMB 2.1 billion and whether the final dividend is raised beyond the announced level (unverified); PTFE/AI-chain (NVIDIA Rubin Ultra backplane) order certifications are a thematic option, excluded from base-case earnings. Falsification triggers: R32 spot below RMB 50,000/ton, an upward revision in the official quota total, or FY2026 attributable earnings below RMB 1.8 billion.
Key evidence:
The hard supply-side constraint is the foundation of this round's higher earnings center: 2026 third-generation physical quotas of 798,800 tons rose only 0.75%, no new capacity can enter, and quota trading accounts for only 3-5% of the total. But equating "total freeze" directly with "48% margin maintained" skips the other two terms of the earnings equation—2026H1 the company itself noted "certain raw material costs have risen" (anhydrous hydrofluoric acid rose from RMB 8,500-9,000 at the start of the year to RMB 15,700-17,000/ton); on the demand side, August domestic AC production schedules at -24.1% are approaching the combined volume-price warning threshold. Observable samples of 45%+ margins span only four half-year periods (44.93% → 48.51%), all within a single up-leg at ten-year price highs—pro-cyclical extrapolation. What we believe is "the earnings floor has been lifted by the quota system," not "peak earnings extended linearly."
Key evidence:
The quality of this "cheapness" requires honest qualification. First, discount-rate sensitivity: at WACC of 8%/10%/12%, implied normalized attributable earnings are RMB 1.11/1.39/1.67 billion respectively—the 12% case overlaps with the mid-cycle estimate (RMB 1.62 billion), so the claim that "the market pays nothing for quota-driven earnings" does not hold; the accurate statement is that the market has priced the neutral pullback path described in C5. Second, the "asset floor" has cracks: 2026H1 trade receivables (incl. notes) of RMB 3.847 billion, +56.7% in half a year (revenue only +8%), with the 91-180 day aging bucket rising from RMB 763 million to 2.148 billion (×2.8), unexplained by the company; of the RMB 6.065 billion net cash, the portion belonging to non-wholly-owned subsidiaries such as Dongyue Silicon (NCI equity ~29% of total equity) must first satisfy minority shareholders and their own capex—counting it fully as parent-disposable value would overstate the protection. Below-book + net cash provide a cushion, not a hard floor: H-share chemicals hovering around 0.9x PB is not uncommon.
Key evidence:
The twin engines are real cash flow: silicones swung from a FY2025 loss of RMB 52 million (including production-accident downtime losses) to a 2026H1 profit of RMB 236 million, and fluoropolymers benefit from recovering AI/semiconductor/new-energy demand. But two discounts must be applied: first, the silicone segment margin is only 9.02%, with the price recovery resting entirely on industry-coordinated production cuts (operating rate 62.9%); the precedent of DMC falling ~65% from its 2021-22 peak shows a restart means a stall; second, the scissors gap of "strong group profit growth but lagging attributable growth" is structural—the attributable/profit-for-the-period capture ratio fell from 73.7% in 2025H1 to 62.9% in 2026H1, and will keep declining as silicones (Dongyue Silicon minority interest ~41%) gain weight; the market prices attributable earnings, so this discount has a fundamental basis.
Key evidence:
After the cancellation of 521 million shares in 2024 plus the tripling of the FY2025 dividend, the share price still retraced ~40% from its June high—this fact sequence shows: attributing the H-share discount mainly to insufficient dividends is wrong; what the market truly doubts is the persistence of refrigerant earnings, plus the liquidity discount of Hong Kong-listed chemicals and the governance structure (Chairman also serving as CEO, deviating from Corporate Governance Code provision A.2.1). Therefore, if the March 2027 annual results raise the payout ratio to 40%+ (implying DPS of ~HKD 0.57, yield ~4.2%) or launch a first on-market buyback, the significance lies in confirming management's judgment of earnings sustainability with real money—a signal, not an engine, of re-rating; if the payout ratio stays at 28.6% with no buyback, inefficient retention of RMB 6 billion net cash will keep suppressing ROE (~8% in 2025; ~13% excluding net cash).
Key evidence:
The weakening of demand-side leading indicators is real, but with three qualifications: August -24.1% (CCIIN) and September -6.5% (AVC) come from different agencies, and the latter's decline has clearly narrowed; the -68.7% export drop reflects the high base of H1 2025 front-loaded exports and quota reallocation toward domestic use, while end-market AC exports were only -4.7% for Jan-Jun; and spot prices have not loosened to date. Applying a 78-88% pass-through: if the R32 average price falls to RMB 55,000/ton (-RMB 10,000), 2027 attributable earnings would be ~RMB 2.1 billion, implying a PE of ~9.5x at the current price—right at the H-share chemicals midpoint; a fall to RMB 40,000 would shift the attributable range down from RMB 2.2-2.6 billion to RMB 1.9-2.3 billion. The mean-reversion logic of "100th percentile must fall" also needs amendment under the quota regime: supply constraints strip historical percentiles of their reference power (R32 was similarly at a historically low percentile in early 2024, then nearly quadrupled over two years). Our joint ruling on C2 and C5: the current price ≈ fair value under C5's neutral path; excess returns can only come from "R32 holding above RMB 60,000+" or "an upward shift in the valuation anchor once the quota-extension narrative is confirmed."
| Metric (RMB) | FY2023 | FY2024 | FY2025 | 2026H1 |
|---|---|---|---|---|
| Revenue (RMB 100mn) | 144.93 | 141.81 | 143.55 | 80.60 (+8.0%) |
| Net profit attributable (RMB 100mn) | 7.08 | 8.11 | 16.42 | 10.27 (+31.8%) |
| Recurring net profit (this report's estimate, RMB 100mn) | 7.70 | 9.23 | 19.28 | 12.99 (+65.2%) |
| Gross margin | 16.81% | 21.62% | 30.81% | 37.18% |
| Net margin (profit for the period/revenue) | — | — | 15.21% | 20.27% |
| Operating cash flow (RMB 100mn) | 13.76 | 20.72 | 37.06 | 20.88 (+38.7%) |
| Free cash flow (OCF − capex, RMB 100mn) | -5.42 | 2.71 | 20.41 | 12.33 |
| Cash and equivalents (period-end, RMB 100mn) | 25.47 | 24.70 | 50.05 | 60.67 |
| Interest-bearing debt (RMB 100mn) | — | — | 0.02 | 0.0018 |
| Debt-to-asset ratio | 22.83% | 16.55% | 14.41% | 17.89% |
| Dividend per share (HKD) | 0.10 | 0.10 | 0.30 (unverified) | No interim dividend |
Note: Recurring net profit is this report's own measure (attributable earnings + goodwill/receivables/PP&E impairments and disposal losses − government subsidies − disposal gains − tax provision reversals and other one-offs, without tax-rate or NCI allocation adjustments); 2026H1 exclusions include goodwill impairment of RMB 160 million, receivables impairment of RMB 52 million, PP&E disposal loss of RMB 59 million, and back taxes of RMB 61 million, with government subsidies of RMB 59 million added back net. The company does not disclose a Non-GAAP measure.
Drivers of metric changes (items with YoY ≥ ±20%, each with the company's explanation):
In 2026H1, revenue was RMB 8.060 billion (+7.99%) and net profit attributable to shareholders was RMB 1.027 billion (+31.80%), landing right at the lower bound of the July 9 positive profit alert of "growth exceeding 31%"—management guidance continues its style of being "precise and conservative" (the FY2025 alert vs. actuals followed the same pattern). Three structural observations:
Business model: Asset-heavy, integrated fluorochemical-silicone manufacturing—purchased fluorspar → anhydrous hydrofluoric acid (~150,000 tonnes/year, No. 6 in China, mostly self-consumed) → refrigerants (world's largest R22 capacity; ~60,000 tonnes of R32 plus newly commissioned 49,000 tonnes) → fluoropolymers (PTFE 55,000–60,000 tonnes, global first tier; PVDF 25,000 tonnes, No. 2 in China; the only domestic player with commercial-scale perfluorosulfonic acid ion membranes) + silicones (600,000 tonnes of DMC monomer, top 3 in China) + chlor-alkali integration. No mining resource endowment, no subscription revenue; refrigerants carry strong pricing power under quota barriers (quarterly price increases in long-term contracts), while silicones/polymers/chlor-alkali prices follow the market. Overseas revenue accounts for 14.4%, and the largest single customer accounts for less than 10%.
Cash content of earnings: OCF/attributable net profit for 2023–2026H1 was 1.94/2.56/2.26/2.03—four consecutive years of full cash conversion with surplus, indicating high book earnings quality. FCF/attributable net profit: -0.77/0.33/1.24/1.20—at the cyclical bottom (2023), capex consumed all profit; in the upcycle (from 2025), capex converged (RMB 1.918 → 1.801 → 1.665 billion) and the company turned into a cash cow. What needs watching is working capital: the 2026H1 increase in receivables plus inventory of RMB 1.24 billion was 2.1x the revenue increase (RMB 597 million), with funding pressure concentrated in receivables.
Return on capital: Estimated ROIC for FY2025 was about 14.4% (annualized ~21.3% in 2026H1), above the chemical industry average; but attributable ROE was only about 8% (9.5% annualized in 2026H1; ~13.2% excluding RMB 6.065 billion of net cash)—RMB 6 billion of zero-yield cash depresses headline ROE by roughly 5 percentage points, serving both as a safety cushion and a drag on capital efficiency.
Maintenance capex: CapEx/depreciation was 1.58 (2023) → 1.51 (2024) → 1.22 (2025) → 1.27 (2026H1 annualized)—converging from expansionary to near maintenance levels (<1.5). This is not a capital-black-hole business, but its asset-heavy nature means free cash flow depends on the cycle.
Moats and red flags: Moat = existing quotas (administrative barrier, the hardest) + cost and volatility-resistance from four-chain integration (fluorine, silicon, chlorine, membranes) (2026H1 gross margin of 37.18% vs. Juhua's 28.23% in 2025) + technology positioning in high-end categories (PFSA membranes, electronic-grade fluoromaterials). Three red flags: highly concentrated earnings (refrigerants are 63.2% of segment results); high share of one-off items in attributable profit (2026H1 net -RMB 272 million, 26.5% of total); NCI leakage of 37.2% and trending upward.
Consistency of words and deeds: pragmatic, no record of exaggeration. Verifiable promise-delivery sequence: ① the 2025 annual report committed to completing and commissioning the energy center by 2026H1 → the interim report confirmed "successfully commissioned"; ② the July 9, 2026 profit alert of "net profit growth exceeding 31%" → actual +31.80%, precisely delivered at the lower bound; ③ the 2024 annual report expected "refrigerants to provide a stable growth driver" → FY2025 refrigerants segment results +183.71%; ④ Dongyue Silicon Materials guided attributable profit of RMB 424–444 million (+905%~952%) → group silicones segment results of RMB 236 million and NCI +118.6%, directionally consistent (the subsidiary's formal interim report is not in this document set; marked as partially delivered). Additionally, the March 26, 2026 clarification announcement was merely a correction of a typo in the final dividend payment date, with no bearing on financial data.
Shareholder friendliness: improving but not yet sufficient; rated "neutral leaning friendly". Positives: the off-market buyback and cancellation of 521 million shares at the October 2023 industry bottom (~23% of share capital, at a cost of about HK$3.7 billion) was a rare countercyclical move among HK-listed chemical companies; FY2025 dividend tripled (HK$0.10 → 0.30, unverified); no record of share issuance/placement/convertible bond dilution. Negatives: a 28.6% payout ratio is low given peak earnings; two consecutive years without an interim dividend; no buybacks since 2024; the terminated share option trust sold about 76.71 million shares (4.43% of share capital) into the market within 18 months and has been wound down to zero—the stabilizing bid has disappeared.
Risk signals: Zhang Jianhong serves as both Chairman and CEO (deviating from Corporate Governance Code provision A.2.1; the board describes itself as having "strong leadership"); Cayman-incorporated holding structure with assets highly concentrated at a single site in Zibo, Shandong (>95% of non-current assets in China); legacy baggage largely cleaned up (Xinhualian's RMB 310 million deposit mostly recovered; real estate essentially exited; the related-party loan to Zhangjiajie Xinye has been repaid).
| Segment (2026H1) | Revenue Share | Segment Profit Margin | Segment Results YoY | Business Logic |
|---|---|---|---|---|
| Refrigerants | 31.87% | 48.51% | +20.99% | Policy dividend under quota constraints; world's largest R22 capacity; quarterly price increases in long-term contracts |
| Silicones | 32.42% | 9.02% | +2,594.93% | DMC and downstream processing, mainly via A-share listed Dongyue Silicon Materials; first year of cyclical reversal |
| Fluoropolymers | 26.56% | 20.49% | +69.21% | PTFE/PVDF/fluoromembranes; recovering AI/semiconductor/new energy demand + price increases |
| Dichloromethane & Caustic Soda | 5.78% | 12.80% | -72.11% | Commodity products supporting refrigerants; market-priced; prices declining |
| Others | 3.37% | Loss of RMB 7 million | Loss narrowed 91.7% | By-products + property + power & heat; losses narrowed after legacy power plant impairments were cleared |
Profit driver: Refrigerants, with 31.87% of revenue, contribute 63.2% of total segment results—the main profit driver is separate from the main revenue driver (silicones). Second tier: fluoropolymers RMB 439 million (22.2%) + silicones RMB 236 million (11.9%) together account for 34%, and contributed 59% of the increment.
Gross margin spread is 39.5pp (refrigerants 48.51% vs. silicones 9.02%): the gap stems from administrative barriers—refrigerant supply is locked by quotas with oligopolistic tacit pricing; silicones are fully market-driven, with overcapacity only just emerging from "industry-wide losses," and the 9% margin rests on coordinated production cuts at a 62.9% operating rate. Two businesses within the same company have vastly different bargaining power and should be valued differently: the former deserves a "quasi-franchise" premium, the latter a cyclical mean-reversion treatment.
Accounting red flags:
Inter-period consistency: Contradictory R&D KPI disclosure—FY2025 annual report states "874 cumulative granted patents" vs. 2026 interim report "478 patents held at period end"; 12 new patents in half a year cannot explain 874→478; likely a change in definition, unexplained by the company (inconsistent); receivables growth vs. revenue growth divergence over three periods (unexplained, inconsistent); tax rate and disposal losses (consistent or explained).
Overall judgment: receivables are the only substantive red flag requiring sustained vigilance (note-based settlement + aging extension; a price pullback in 2027 would amplify collection risk); goodwill and impairment issues are, by contrast, near clearance. No signs of profit manipulation found—OCF exceeding net profit for four consecutive years is strong counter-evidence.
Current market data (as of September 1, 2026 close): Share price HK$13.45; market cap HK$23.305 billion (≈RMB 19.98 billion). PE(TTM) of 10.71x—at the 3rd percentile of the past year, but this is the classic pattern of "cyclical peak earnings depressing headline PE"; the percentile is for reference only, not a cheap/expensive signal. Hand-calculated PB of 0.93x (2026H1 book value per share RMB 12.46 = HK$14.53); third-party data sources show 1.33x (lagged book value series), roughly the 67–71% percentile over 3/5/10 years. FY2026E PE ~9.5x (attributable profit midpoint RMB 2.1 billion); FY2027E ~7.8x (midpoint RMB 2.55 billion). Dividend yield 2.23% (based on announced dividends, unverified).
Peer comparison (A/H definitional differences are significant; multiples are TTM):
| Company | PE(TTM) | PB | ROE | 2026H1 Attributable Profit Growth |
|---|---|---|---|---|
| Dongyue Group (00189.HK) | 10.71 | 0.93 (hand-calculated) | 2025 ~8% (13.2% ex-cash) | +31.8% |
| Juhua Co. (600160.SH) | 24.06 | 4.78 | 2025 19.79% | +29.2% |
| Sanmei Co. (603379.SH) | 16.91 | 4.26 | 2025 28.36% | +7.6% |
| Yonghe Co. (605020.SH) | 21.07 | 2.80 | 2025 13.06% | +89.0% |
Dongyue trades at roughly a 37–55% discount to A-share peers—a substantial portion of which is an H-share liquidity/holder-structure discount (evidenced by the non-convergence of the discount even after the large 2024 buyback and tripled dividend), not entirely a fundamental gap; Dongyue's low ROE genuinely reflects idle net cash and the NCI structure.
Market-implied expectations: Excluding net cash per share of HK$4.08, operating value is HK$9.37/share; capitalized at a 10% WACC → implied normalized attributable profit of ~RMB 1.39 billion, equivalent to pre-quota 2023–24 levels; equivalently, the market assumes the R32 average price falls back to around RMB 55,000/tonne in 2027 and never recovers—i.e., "half the quota dividend is given back, with no re-rating." Sensitivity: WACC 8% → implied RMB 1.11 billion; 12% → RMB 1.67 billion (overlapping the mid-cycle estimate). Our verdict: the market has largely priced the C5 neutral path; there is an incremental expectation gap but a modest one (~10–15%); the prevailing sell-side range (Futu as of 2026-08-31: mean 18.12 / low 15.25 / high 21.67 HKD) is 13%–35% above the current price—no pessimistic bids on the institutional side.
Three-tier value (EPV): Asset value HK$14.53/share (PB 1.0x, including net cash of HK$4.08); EPV with zero growth ~HK$15.0/share (normalized EPS HK$1.09: mid-cycle segment results of RMB 2.8 billion × 0.58 attributable coefficient = RMB 1.62 billion, corresponding to a mid-cycle R32 average price of RMB 40,000–45,000/tonne; WACC 10%); growth option ~-HK$1.5 (-11%)—far from paying for options such as AI/PTFE, proton membranes, and fourth-generation refrigerants, the market is discounting even the zero-growth value. A note on normalizing assumptions: RMB 1.62 billion is conservative versus the 2026H1 annualization (~RMB 2.1 billion recurring attributable profit halved and annualized), and double the pre-quota level (RMB 700–800 million), reflecting the judgment that "the quota system lifts the midpoint but does not guarantee peak earnings."
Three scenarios and odds (12 months):
| Scenario | Probability | Fair Value Range | vs. Current Price | Key Drivers |
|---|---|---|---|---|
| Bear | 25% | HK$7.3–10.8 | Midpoint -32% | R32 falls to RMB 30,000–40,000 (annual long-term contract cuts exceed 10–15%), 2027 attributable profit RMB 1.8–2.3 billion, H-share chemicals trough PE 6–7x; overlaps the 52-week low of 9.65 |
| Base | 55% | HK$12.9–17.5 | Midpoint +12% | R32 midpoint holds above RMB 45,000, 2027 attributable profit RMB 2.3–2.6 billion, exit multiple 8–10x (anchors: Sinopec Corp 9.0–10.8x + a 40% H-share discount to A-shares + 60–75% of its own 1-year median PE of 13.3x; three anchors independent of the current price) |
| Bull | 20% | HK$20.0–26.3 | Midpoint +72% | Refrigerants hold above RMB 55,000 with PTFE/AI volume ramp, 2027 attributable profit RMB 2.7–3.0 billion, re-rating to 11–13x (converging toward implied sell-side multiples) |
Probability-weighted fair value is ~HK$15.25 (+13.4%); the base-case fair range of HK$12.9–17.5 is the target price range, with a midpoint of HK$15.1, +12.3% versus the current price. The distribution is positively skewed but modest: the current price is already inside the base-case range, buffered below by the asset tier and net cash (net cash is ~30% of market cap), and capped above by the "peak earnings" narrative—this is the odds structure behind the Neutral rating.
House forecasts vs. management/sell-side, side by side:
| Source | FY2026E Attributable Profit | FY2027E Attributable Profit |
|---|---|---|
| This report | RMB 2.05–2.2 billion | RMB 2.3–2.6 billion |
| Management | No quantitative guidance ("strong H1 growth makes a good start to the year") | — |
| Sell-side (Futu consensus) | Implied ~RMB 2.1 billion (basis of Huatai's August 25 target price hike) | ~RMB 2.4–2.7 billion |
Conclusion: reasonably cheap, modestly so. Separate quality from price: the business quality is real but not top-tier (ROE ex-cash ~13%, only slightly above WACC; the quota dividend is a policy supply constraint, not a cost advantage); on price, the market has already applied a full cyclical discount (PB 0.93x, FY2027E PE 7.8x), below mid-cycle zero-growth value (EPV ~HK$15.0), but by a modest margin (~+11% on the EPV basis, ~+13% on the scenario-weighted basis) and sensitive to normalization assumptions. Margin of safety is roughly -4% (base-case lower bound of 12.9 is slightly below the current price). The undervaluation stems mainly from "H-share chemicals discount + cyclical-peak fear"; a re-rating requires catalysts to be delivered, not just time.
Dongyue truly competes on two parallel tracks. Fluorochemicals: China's refrigerant market grew from RMB 11.72 billion in 2016 to ~RMB 24.55 billion in 2024 (Zhiyan Consulting basis, CAGR ~9.7%); China's overall fluorochemical market was ~RMB 58.56 billion in 2022 (China Fluoro-Silicone Organic Materials Industry Association basis). The global fluoropolymer market is ~US$8.7–10.5 billion in 2025 (Fortune Business Insights/Straits Research; aggregator figures pending verification), with China holding ~55% of global PTFE capacity (2025: 175,000 tonnes in China / 320,000 tonnes globally). Silicones: China's apparent DMC consumption in 2024 was 1.82 million tonnes (+21%, Baichuan Yingfu), with year-end intermediate capacity of 3.44 million tonnes.
The defining industry variable for fluorochemicals is the quota system: the Kigali Amendment (effective for China in September 2021) freezes HFCs in 2024 at baseline (2020–2022 average × 85%), with a first 10% cut in 2029, -30% in 2035, and -80% in 2045; second-generation R22 has been cut to 32.5% of baseline by 2025 under the Montreal Protocol, with full phase-out in 2030. Third-generation physical quotas for 2026 total 797,800 tonnes (only +0.75% vs. 2025), and the 2027 draft for comment confirms a flat total of 1.853 billion tCO₂ (2026-08-24). With volumes locked, growth comes almost entirely from price: third-party estimates put R32's long-term equilibrium midpoint at ~RMB 80,000/tonne (Tianxia Factory Industry Research Institute, pending verification) and the theoretical 2027 marginal price at RMB 110,000–130,000. Fluoropolymers see a global CAGR of ~5–7% over 2026–2034, and silicone demand grows ~10–15% annually, yet there are zero new capacity plans before end-2026.
The chain: fluorspar (97%-grade concentrate at RMB 3,300–3,500/tonne in 2025; mining quotas ~6 million tonnes/year plus an export quota system) → anhydrous hydrofluoric acid (China capacity ~2.8 million tonnes, 65% of global; operating rate only ~70%, industry-wide oversupply; Dongyue's AHF ~150,000 tonnes, No. 6 in China, mostly self-consumed) → refrigerants (R32 ~RMB 62,500/tonne, 2026Q2 long-term contract) / fluoromonomers–polymers (PTFE ~RMB 50,000 → lithium-battery PVDF RMB 80,000–100,000 → perfluorosulfonic acid membranes RMB 2–3 million/tonne) → downstream air conditioning (R32 penetration ~75%), automotive/cold chain (R134a), heat pumps, lithium batteries/PV/semiconductors/AI. Value density rises roughly a thousand-fold from ore to membrane, and the largest profit-retaining link is quota-protected refrigerants in the midstream (Dongyue's 2026H1 refrigerants segment pre-tax margin was 48.5%), followed by high-end polymers. Dongyue captures the full chain vertically, with a deeper downstream processing mix than pure refrigerant players; the cost is sensitivity to purchased fluorspar prices (fluorspar is at historical highs). On the silicone side: Dongyue Silicon Materials' 600,000 tonnes of monomer ranks top 3 nationally; relative to Hoshine (~26% capacity share) it sits in the second tier, competing on fluoro-silicon synergy from co-located park facilities and its downstream processing mix.
Demand side: refrigerants = air-conditioner production + aftermarket refrigerant top-ups + heat pumps. Total AC output for the 2026 cooling year was approximately -11.1%; August domestic production schedules fell -24.1% (Industry Online) and September -6.5% (Aowei, narrowing decline); exports diverged — AC exports to the EU rose +43.2% in 2026H1 (European heatwave), but July direct R32 refrigerant exports were 2,080 tonnes, -68.7% YoY (high 2025 front-loading base + quota tilted toward domestic use). Fluoropolymer demand = lithium battery binders/PV backsheets (PVDF combined ~65%) + semiconductors/AI servers (ePTFE/electronic grade, localization rate <30%) + hydrogen energy (PFSA membranes, ~2 million ㎡ in 2025 → forecast ~20 million ㎡ by 2030). Supply side: refrigerant supply is inelastic — quotas are granted only to producers with actual production during the baseline period, secondary trading accounts for only 3-5% of the total, and cross-species adjustment does not increase total CO₂-equivalent; silicone supply shows negative elasticity — zero new capacity in 2025-2026 + the Industry Standard Conditions (2025) + coordinated production cuts (operating rate 62.9%) + pre-sale order books full through late September. Third-party estimates put 2025 R32 demand at ~520,000 tonnes vs quotas of ~380,000 tonnes (Tianxia Factory Research methodology; there is a methodological difference from the national R32 quota of ~280,000 tonnes derived from company shares — the gap direction is consistent but the magnitude awaits verification). Tight balance is the root cause of price increases.
Concentration: HFCs CO₂-equivalent CR6 ~77% — Juhua ~27%, Sanmei ~17%, Dongyue ~12%, Yonghe ~8%, Sinochem Lantian ~7%, Haohua ~6%; R32 quota CR3 ~78% (Juhua/Dongyue/Sanmei); R22 quota: Dongyue ranks first nationally at 29.46% (43,000-43,900 tonnes), Juhua second at 23.79%. Silicone CR3 ~58% (Hesheng 26%/Dongyue Silicon 17%/Xin'an 15%). Entry barriers: refrigerants = quotas (the strongest administrative barrier; new players go to zero after 2024); fluoropolymers = process + certification (semiconductor-grade certification takes years); PFSA membranes = technological monopoly (Chemours' Nafion held a monopoly for 50 years; Dongyue is the sole domestic producer at scale, with >60% share in PEM water-electrolysis membranes). Competitive dynamics: the quota system ended the industry-wide loss-making price war of the 2020-2022 baseline period, replacing it with an oligopolistic accord of "profit maximization within quotas" — price-war risk is extremely low, and competition shifts to 4th-generation refrigerants (R1234yf patent-circumvention race) and high-end categories.
The policy matrix is a full tailwind through 2028: quota freeze extension (draft for comment) + the EU PFAS restriction actually suppresses 4th-generation HFOs (R1234yf is a PFAS with high TFA conversion; penetration in new Chinese vehicles is only 8-10%) → the third-generation lifecycle is administratively and judicially extended in parallel; ECHA leans toward "tiered exemptions for industrial uses" of fluoropolymers (clarity in 2027-28). "Anti-involution" policies (silicone standard conditions + coordinated production cuts) put a floor under silicone prices. Distant ceiling: R22 goes to zero by 2030 and HFC reductions start from 2029 — the industry logic then switches to "reduction-driven price increases," which may actually extend the dividend for quota holders. For cycle positioning and historical templates see Chapter 13.
Leader + structural positioning: R22 quota No.1 nationally + R32 No.2 + PTFE first tier globally (~34% of China's capacity) + PVDF No.2 nationally + PFSA membranes sole domestic producer. Share is essentially locked in statically (the quota confirmation period has passed); share trends depend on structural upmigration into high-end categories (electronic-grade PTFE, proton membranes, 1,000-tonne R1234yf layout). A methodological difference worth noting: on the company's own reporting basis, its R32 quota is 56,300 tonnes, 20.09%, ranked No.2 nationally, while third-party (Tianxia Factory Research) estimates put Dongyue's total HFC CO₂-equivalent share at ~12%, ranking third — the gap stems from the "single-species physical volume vs all-species CO₂-equivalent" methodology; the two are not contradictory. Three layers of moat: quota stock (administrative) > fluorine-silicon-chlorine-membrane integration (cost + volatility resistance) > high-end category technology (PFSA/electronic grade). Relative weaknesses: no owned fluorspar mine (exposed on costs), silicone scale in the second tier, and an H-share liquidity discount.
Historical cycle templates (last three refrigerant cycles + current): ① 2013-2015 (start of R22 quota cuts): R22 rose from 8,800 to ~14,000 RMB/tonne (+59%), then fell with the post-property cycle; ② 2016-2018 (supply-side reform + AC restocking): peaked in 2018Q2, followed by ~2 years of decline; ③ 2021 pulse (dual energy control): R22 spiked to 26,000 RMB then round-tripped within 1-3 months; additionally, 2020-2022 was a ~3-year industry-wide loss-making price war for baseline quota grabbing. Current round (the 4th, institutional): triggered by the quota system's implementation in January 2024; R32 rose from ~17,000 to 62,500 RMB by June 2026 (+268%), already lasting ~2.6 years — both amplitude and duration exceed history — because it is underpinned by institutions (freeze through 2028); the historical "2-year peak" template is highly likely to fail under the quota regime, though a demand collapse triggering an overshoot cannot be ruled out.
Current percentile: R32 spot ~64,500-65,500 RMB/tonne (early September), at the ~100th percentile since 2016 and 2.8x the ten-year average (~23,000); R134a ~63,500-68,000. Silicone DMC at 13,500-13,800 RMB/tonne is only ~21% of the 2021 peak (33,000) and +29% off the July 2025 ten-year low — the two core businesses sit at completely different cycle positions: refrigerants in the late stage of a high, silicones in the first year of recovery from the trough.
Supply response: refrigerant quotas frozen through 2027-2028 (zero growth at the ~797,800-tonne level), no new entrants; in the 2026 R22 quota allocation Dongyue's 43,000 tonnes ranks first; silicones have zero new capacity before end-2026, with supply appearing as existing-capacity maintenance and production cuts. Conclusion: through 2028, the supply curves of both chains are price-friendly; a cycle peak can only be triggered by demand (AC production schedules/exports) or policy (quota loosening), not by supply-side restarts.
Through-cycle earnings: normalized (mid-cycle) EPS 0.94 RMB (1.09 HKD) — segment earnings of 2.8 billion RMB (refrigerants 1.6 + silicones 0.3 + polymers 0.75 + chlor-alkali 0.15) × 0.58 parent-attribution coefficient; corresponding to a mid-cycle R32 average price of 40,000-45,000 RMB (65% of current price, nearly 2x the pre-quota decade). Trough EPS 0.46 RMB (0.54 HKD) — anchored to 2024 actual net profit attributable of 811 million RMB (the true earnings-trough year, R32 average ~16,000-17,000; note the price trough in 2020 and the earnings trough in 2024 are not the same year). The current PE is a "high position, low PE" pattern: TTM 10.7x is built on quota-cycle-high earnings, and per cyclical-stock discipline is not a cheap signal; on a normalized basis the current price corresponds to ~12.3x (13.45÷1.09) — in the peer median band (upper part of the H-share chemicals 8x±5x range). Sensitivity: normalized PE 8x → 10.9 HKD (-19%); 10x → 10.9+25% ≈ 13.6 HKD (≈ current price); 13x → 17.7 HKD (+32%) — i.e., the current price ≈ "mid-cycle earnings × 10-11x"; the odds are far more elastic to normalized earnings assumptions than to the discount rate.
Downside stress test: scenarios of R32 average price falling to 50,000/40,000/30,000 RMB imply 2027 net profit attributable of ~2.3-2.6/1.9-2.3/1.8-2.1 billion RMB (pass-through 78-88% × parent-attribution coefficient 0.52-0.58); in an extreme trough (R32 ~13,000), net profit falls to 600-900 million RMB, corresponding to ~7.0 billion HKD market cap at 8x PE (~-70% vs current, consistent with the bear-case floor). Trough balance-sheet test: net cash of 6.065 billion RMB + trough-year OCF of ~1.5-2.0 billion RMB (2024 actual 2.07 billion as evidence) ≥ trough-year capex of 1.5-1.7 billion RMB + dividends of ~500 million RMB — the trough is an earnings and valuation risk, not a solvency risk; net cash is sufficient to ride it out.
Management cycle discipline: a positive. Capex narrowed for three consecutive years during the upcycle (1.918 → 1.801 → 1.665 billion RMB), with expansion limited to in-quota R32 +49,000 tonnes and the energy-center cost-reduction project (harvesting profit pro-cyclically rather than doubling down on expansion); in October 2023, at the industry bottom, it counter-cyclically bought back and cancelled 23% of share capital (~7.1 HKD/share), and FY2025 dividends tripled — this "buy back at the bottom, distribute in the upcycle" counter-cyclical capital allocation discipline is rare among peers. The only blemish: no return-on-investment commitment yet given for the redeployment of 6.0 billion RMB net cash during high-earnings periods (new projects exceeding 1.0 billion RMB).
Overall rating: Neutral, confidence 0.55, on a 12-month horizon. The quota system's policy supply constraint through 2028 is the foundation of this round's earnings; 2026H1 has already delivered it with 31.8% growth in net profit attributable and a 37.18% gross margin. After the stock's -28% decline, the current price of 13.45 HKD (PB ~0.93x) has priced in a "moderate earnings pullback"; we estimate it remains reasonably undervalued by only ~10-15% — not enough to constitute a high-conviction opportunity, but with net cash and asset-layer buffers on the downside and three verifiable catalysts on the upside (October quota final document, Q4/annual long-term contracts, the March 2027 annual report dividend). Strategically, the current level suits existing holders with disciplined reassessment against downside-trigger conditions; for incremental capital, thicker odds appear at one of two points: panic selling accompanying an R32 spot pullback to the 50,000-55,000 RMB band (if the quota framework is unchanged), or the right side after annual long-term contract renewal price increases are confirmed.
Key risks: ① R32 pullback from highs exceeding expectations (annual contract declines >10-15%) — every 10,000 RMB/tonne drop reduces net profit attributable by ~400-500 million RMB; ② marginal policy shift on quotas (precedents of eased cross-species transfers have appeared, with the 245fa cap raised from 30% to 50%); ③ receivables quality deterioration (+56.7% half-yearly, aging extending, amplified when prices fall); ④ shareholder returns persistently below earnings levels (inefficient retention of 6.0 billion RMB net cash entrenching the discount); ⑤ H-share liquidity discount failing to converge. A single event to watch as a disconfirming signal: refrigerant exports sustaining YoY declines of over -50% with no recovery in Q4.
Monitoring points (next 6-12 months): end-October quota final document (whether the 1.853 billion tCO₂ total holds) → Q4 contract settlement and Dec-Jan annual contract negotiations → R32 spot warning lines at 50,000/63,000 RMB → monthly customs exports (R32 back above 4,000 tonnes in a single month as a recovery signal) → DMC production-cut alliance September meeting and peak-season actual orders → 2027-03 annual report (two lines: net profit attributable 2.1 billion RMB+/payout ratio 40%+) → Shengyi Technology/Dongyue electronic-grade PTFE certification orders → southbound capital flows for 5 consecutive days.